| Drug Name |
Finerenone |
| Drug ID |
BADD_D02557 |
| Description |
Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus.[A236519,L34739] Patients with kidney disease, would originally be given [spironolactone] or [eplerenone] to antagonize the mineraclocorticoid receptor.[A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors.[A236544] Eplerenone is more selective and has longer lasting effects.[A236544] More selective nonsteroidal mineralocorticoid antagonists such as [apararenone], [esaxerenone], and finerenone were later developed.[A236544] So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved.[A236544,L34739]
Finerenone was granted FDA approval on 9 July 2021.[L34739] |
| Indications and Usage |
Finerenone is indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus.[L34739] |
| Marketing Status |
approved; investigational |
| ATC Code |
C03DA05 |
| DrugBank ID |
DB16165
|
| KEGG ID |
D10633
|
| MeSH ID |
C576501
|
| PubChem ID |
60150535
|
| TTD Drug ID |
D0NV5O
|
| NDC Product Code |
50419-541; 12527-0640; 50419-540; 12527-0541; 50683-0540 |
| UNII |
DE2O63YV8R
|
| Synonyms |
finerenone | kerendia | BAY 94-8862 |
